Statement of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities:
Net income (loss)	$ (3,978,433)	$ (94,406)
Adjustments to reconcile net income to net cash provided by (used for) operating activities:
Depreciation expense	3,020
Stock-based compensation expense	579,565
Compensatory loan increases/(decreases)	(180,000)	60,000
Noncash write-off of related party loan	71,672
Legal settlement payable in stock	1,597,500
Changes in operating assets & liabilities:
(Increase)/decrease in prepaid expenses	(44,102)
Increase/(decrease) in accounts payable and accrued expenses	290,566	8,694
Increase/(decrease) in accrued interest payable - related party	(25,894)	14,695
Increase/(decrease) in non-current legal settlement payable	145,000
Net cash provided by (used for) operating activities	(1,541,106)	(11,017)
Cash Flows From Investing Activities:
Purchase of fixed assets	(100,721)
Deposit paid toward Specialty Pharmacy acquisition	(50,000)
Net cash provided by (used for) investing activities	(150,721)
Cash Flows From Financing Activities:
Proceeds from (paydowns of) related party loans	(33,934)	10,992
Proceeds from sales of common stock	3,331,000
Net cash provided by (used for) financing activities	3,297,066	10,992
Net Increase (Decrease) In Cash	1,605,239	(25)
Cash At The Beginning Of The Period		25
Cash At The End Of The Period	1,605,239
Schedule of Non-Cash Investing and Financing Activities
Related party loans	(71,672)	60,000
Supplemental Disclosure
Cash paid for interest	0	0
Cash paid for income taxes	$ 0	$ 0